Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Seth Berry

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Clinical Therapeutics|August 7, 2013
Efficacy and tolerability exposure-response relationship of retigabine (ezogabine) immediate-release tablets in patients with partial-onset seizuresDebra J Tompson, Christopher S Crean, Russell Reeve, et al.
International Immunopharmacology|October 3, 2021
Population pharmacokinetic simulation of varied Immune Globulin Subcutaneous (Human), 20% solution (Ig20Gly) loading and maintenance dosing regimens in immunoglobulin-naïve patients with primary immunodeficiency diseasesZhaoyang Li, Todd Dumas, N Seth Berry, et al.
British Journal of Clinical Pharmacology|April 20, 2004
Modelling the cardiovascular effects of ephedrineAdam M Persky, N Seth Berry, Gary M Pollack, et al.
International Immunopharmacology|April 6, 2019
Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseasesTodd Dumas, N Seth Berry, Martin Wolfsegger, et al.
Clinical Pharmacology in Drug Development|July 26, 2021
Population Pharmacokinetic Model Development and Simulation for Recombinant Erwinia Asparaginase Produced in Pseudomonas fluorescens (JZP-458)Tong Lin, Todd Dumas, Josh Kaullen, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Clinical Therapeutics|August 7, 2013
Efficacy and tolerability exposure-response relationship of retigabine (ezogabine) immediate-release tablets in patients with partial-onset seizuresDebra J Tompson, Christopher S Crean, Russell Reeve, et al.
International Immunopharmacology|October 3, 2021
Population pharmacokinetic simulation of varied Immune Globulin Subcutaneous (Human), 20% solution (Ig20Gly) loading and maintenance dosing regimens in immunoglobulin-naïve patients with primary immunodeficiency diseasesZhaoyang Li, Todd Dumas, N Seth Berry, et al.
British Journal of Clinical Pharmacology|April 20, 2004
Modelling the cardiovascular effects of ephedrineAdam M Persky, N Seth Berry, Gary M Pollack, et al.
International Immunopharmacology|April 6, 2019
Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseasesTodd Dumas, N Seth Berry, Martin Wolfsegger, et al.
Clinical Pharmacology in Drug Development|July 26, 2021
Population Pharmacokinetic Model Development and Simulation for Recombinant Erwinia Asparaginase Produced in Pseudomonas fluorescens (JZP-458)Tong Lin, Todd Dumas, Josh Kaullen, et al.
Pageof 1